Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares declined 1.14% to $8.65. The company on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -2.87% in last session and finished the day at $8.13. Traded volume was 13.50million shares in the last session and the average volume of the stock remained million shares. The beta of the stock remained 1.42. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) insider ownership is 1.70%.

Just six weeks of Gilead Sciences Inc. (NASDAQ:GILD) hotly anticipated combination pill of ledipasvir and Sovaldi (sofosbuvir), given with or without GS-9669 or GS-9451, cured 95 to 100 percent of people with genotype 1 of hepatitis C virus (HCV) in a small pilot study, MedPage Today reports. Gilead Sciences, Inc. (NASDAQ:GILD) dropped -0.43 percent to $79.58 Friday on volume of 20.47million shares. The intra-day range of the stock was $77.81 to $81.35. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $122.41million.

CEL-SCI Corporation (NYSEMKT:CVM) soared 12.50% after the company announced that its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated its first U.S. clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina. CEL-SCI Corporation (NYSEMKT:CVM)’s stock on Mar 7, 2014 reported a increase of 11.90% to the closing price of $1.41. Its fifty two weeks range is $0.53-$3.09. The total market capitalization recorded $78.88million. The overall volume in the last trading session was 7.41million shares. In its share capital, CVM has 48.22million outstanding shares.

Inovio Pharmaceuticals Inc (NYSEMKT:INO) has reportedly completed the underwritten public offering successfully on Tuesday as the company announced the collection of the total gross proceeds of $63.3 million. On Friday, shares of Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -3.13% to close the day at $3.40. Company return on investment (ROI) is -68.30% and its monthly performance is recorded as 35.46%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) quarterly revenue growth is 61.90%.